For instance, RNA-binding motif protein 17 (RBM17) expression in tumor samples could be used to predict the clinical efficacy of ICI monotherapy in NSCLC patients with a low PD-L1 expression (30). This evidence concerns the gene CD274 and non-small cell lung carcinoma.